Research/Development

Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D

[ad_1]

Exelixis Inc. (NASDAQ:EXEL) is one of the best growth stocks to buy for the next 2 years. On August 29, Exelixis Inc. announced the appointment of Dana T. Aftab, Ph.D., as its new Executive Vice President, Research & Development. In this role, he will oversee all aspects of the company’s drug discovery, translational research, product development, and medical affairs.

Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D

Dr. Aftab has been with Exelixis for more than 25 years, having joined the company in 1998. Most recently, he served as Executive Vice President, Discovery & Translational Research & Chief Scientific Officer since December 2022. He has been a key figure in the discovery and development of the company’s flagship medicine, CABOMETYX (cabozantinib), which is a leading tyrosine kinase inhibitor in the US for treating advanced renal cell carcinoma and advanced neuroendocrine tumors.

This appointment follows the departure of Amy Peterson, M.D., who had served as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer since August 2023.

Exelixis Inc. (NASDAQ:EXEL) is an oncology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers in the US.

While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None. This article is originally published at Insider Monkey.

[ad_2]

Source link

September 5, 2025

Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study

[ad_1]

By Mauro Orru

Roche Holding said its investigational treatment, inavolisib, showed promise in a late-stage study to treat patients with breast cancer.

The Swiss pharmaceutical company said Tuesday that the phase 3 study met its primary endpoint of progression-free survival, showing that inavolisib, in combination with palbociclib and fulvestrant, delivered a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone.

While Roche acknowledged that overall survival data were immature at this stage, it said it had observed a clear positive trend. The inavolisib combination was well tolerated.

The group said inavolisib is an investigational, oral targeted treatment with potential to provide durable disease control.

Write to Mauro Orru at mauro.orru@wsj.com

[ad_2]

Source link

December 4, 2023

Where the Cannabis C-Suite is Missing The Mark on Automation – Cannabis Business Executive – Cannabis and Marijuana industry news

[ad_1]

Where the Cannabis C-Suite is Missing The Mark on Automation – Cannabis Business Executive – Cannabis and Marijuana industry news

skip to Main Content

[ad_2]

Nohtal Partansky

Source link

November 2, 2023

Novartis Says Kidney Drug Phase 3 Trial Reaches Positive Interim Result

[ad_1]

By Adria Calatayud

Novartis said an interim analysis from a phase 3 trial to evaluate its investigational iptacopan drug in patients with kidney disease nephropathy achieved positive results, meeting its primary goal.

The Swiss pharmaceutical company said Monday that an analysis of study data at nine months showed a clinically meaningful and statistically significant reduction in protein in urine. The company said this demonstrated superiority of iptacopan relative to placebo in reducing protein in urine.

The safety profile of the drug was consistent with previously reported data, Novartis said.

Novartis said it plans to review the trial’s interim results with the U.S. Food and Drug Administration to enable a potential regulatory submission for accelerated approval.

The study will now continue to assess the iptacopan’s ability to slow disease progression over two years, the company said. Results from the primary goal at the end of the study are expected in 2025.

Write to Adria Calatayud at adria.calatayud@dowjones.com

[ad_2]

Source link

October 1, 2023

Roche Lung Cancer Drug Shows Promise in Phase 3 Trial

[ad_1]

By David Sachs

Roche said Friday that its Alecensa drug demonstrated the ability to reduce recurrence of lung cancer for patients in the early stage of the disease.

The Swiss pharmaceutical company said the results, from a Phase 3 study of 257 people which compared the treatment with platinum-based chemotherapy, met its primary goal of disease-free survival in people with early-stage non-small cell lung cancer. About half of people with this type of lung cancer experience a recurrence of the disease after surgery, Roche said.

Roche said that it found no unexpected safety issues and will submit the data to global health authorities.

Write to David Sachs at david.sachs@wsj.com

[ad_2]

Source link

August 31, 2023

ServiceNow Posts Strong Earnings and Adds New AI Tools. But the Stock Is Lower.

[ad_1]

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/servicenow-earnings-stock-price-ef3bea69

Updated July 26, 2023 5:00 pm ET / Original July 26, 2023 4:13 pm ET

Order Reprints
Print Article

ServiceNow

posted better-than-expected results for its latest quarter and lifted its full-year outlook.

[ad_2]

Source link

July 26, 2023

Biogen wins accelerated FDA approval for treatment for rare form of ALS

[ad_1]

The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.’s torferson, a treatment for a rare form of amyotrophic lateral sclerosis, or ALS.

The accelerated program is used to approve drugs for serious conditions that have an unmet medical need, where a drug is shown to have an effect on an endpoint that is reasonably likely to predict a clinical benefit to patients.

In…

[ad_2]

Source link

April 25, 2023

FDA pulls preterm-birth drug Makena and its generics from market after 12 years

[ad_1]

The U.S. Food and Drug Administration said Thursday it had reached a final decision to fully withdraw approval of preterm-birth drug Makena and its generics, a full 12 years after the treatment hit the market.

The drug was approved in 2011 using the agency’s accelerated-approval pathway as a treatment to reduce the risk of spontaneous preterm birth in pregnant women who had a history of the condition.

The…

[ad_2]

Source link

April 6, 2023

Disney eliminates metaverse division in cost-cutting purge: report

[ad_1]

The metaverse is among the first victims of Walt Disney Co.’s cost-cutting purge.

The Magic Kingdom is shutting down its next-generation storytelling and consumer-experiences unit, the small division that was developing metaverse strategies, as part of a plan to slash 7,000 jobs, according to a Wall Street Journal report on Tuesday.

Disney…

[ad_2]

Source link

March 28, 2023

Arlington Capital Partners Announces Formation of Eqlipse Technologies

[ad_1]

New platform delivers capabilities across full-spectrum cyber and SIGINT engineering, digital operations and identity management, and advanced R&D to address critical national security missions.

WASHINGTON, March 21, 2023 (Newswire.com)
–
Arlington Capital Partners today announced the formation of Eqlipse Technologies (“Eqlipse” or the “Company”), which is expected to be effective as of the end of the first quarter, 2023. The Company has industry-leading capabilities spanning full-spectrum cyber and signals intelligence (“SIGINT”) engineering, digital operations and identity management, and cutting-edge research and development (“R&D”). Eqlipse utilizes these core capabilities to deliver end-to-end mission-oriented solutions to key national security customers within the Department of Defense (“DoD”) and Intelligence Community (“IC”).

“We are excited to announce the formation of Eqlipse, which is purpose-built to provide our essential national security agencies with the innovation they need as their missions evolve,” said David Wodlinger, a Managing Partner at Arlington Capital Partners. “Eqlipse is launching with a strong foundation built on decades of history and experience working with our customers, a growing portfolio of proprietary technologies, and a cadre of world-class subject matter experts pushing the art of the possible every day.”

Eqlipse supports critical needs across the full cyber domain, including offensive and defensive cyber, SIGINT engineering, computer network operations (“CNO”), and software development. The Company specializes in developing next-generation systems, solving high-performance big data challenges, and building tailored multi-tier data-driven analytic systems. The company is also a market leader in technologies for digital operations and identity management.

“As technology evolves and our infrastructure increasingly shifts to a digital domain, cybersecurity becomes an even more critical component of our national security,” said Dennis Kelly, Chief Executive Officer of Eqlipse. “Eqlipse was created to provide an operational advantage to our customers as their missions evolve to new, virtual battlefields.”

Eqlipse has been solving scientific challenges for high-profile government customers with mission-critical needs for nearly 50 years. Underpinned by world-class scientists and engineers along with state-of-the-art infrastructure, Eqlipse is at the vanguard of fundamental scientific research and technology development. The Company has an established reputation for thought leadership in the areas of photonics, electronics, materials science, and biological and nanoscale technologies, among other disciplines, generating over 100 publications and numerous patents annually in these fields. Building on this distinguished R&D history, Eqlipse continues to mature the most promising research innovations into proprietary technologies with direct mission impact.

Eqlipse has more than 600 employees across three primary locations – Herndon, Virginia, Annapolis Junction, Maryland, and Dayton, Ohio – and more than $200 million in revenue. The employee base is highly educated with more than 115 PhDs and 45% of the workforce holding advanced degrees.

“The name Eqlipse communicates the total alignment of the Company’s innovative culture with the mission needs of our customers,” said Henry Albers, a Vice President at Arlington Capital Partners. “We will continue to invest significant resources behind Eqlipse to recruit industry-leading scientists and engineers, build out state-of-the-art facilities and labs, and fund the IRAD necessary to continue to deliver innovation for the most pressing missions.”

About Eqlipse

Eqlipse Technologies provides products and high-end engineering services to ensure our customers in the Department of Defense and Intelligence Community succeed in their most critical missions. Our industry-leading capabilities in virtual operations, identity management, signals intelligence, full-spectrum cyber and online operations, align with our state-of-the-art scientific research and technology services, ensuring that our essential national security agencies operate at the speed of innovation as their missions evolve to new battlefields. When innovation and mission are in total alignment, you’ll find Eqlipse. For more information: www.EqlipseTechnologies.com.

Source: Eqlipse Technologies

[ad_2]

Source link

March 21, 2023

BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI

[ad_1]

By Colin Kellaher

Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the clinical-stage biopharmaceutical company reported positive results from a pair of Phase 2 studies assessing the potential of its NE3107 drug candidate in Parkinson’s disease and Alzheimer’s disease.

The Carson City, Nev., company said the study of NE3107 in Parkinson’s met both main objectives, with patients treated with a combination of the drug and levodopa seeing meaningful improvements in their motor score and an absence of adverse interactions of NE3107 with levodopa.

BioVie said that based on the study findings, it will proceed with planning the Phase 3 program for discussion with the U.S. Food and Drug Administration.

Meanwhile, BioVie said patients treated with NE3107 in the Alzheimer’s study experienced improved cognition and biomarker levels, with no drug-related adverse events observed.

BioVie shares, which closed Monday at $5.21, were recently up 15% to $5.98 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

[ad_2]

Source link

December 6, 2022

GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint

[ad_1]

By Michael Susin

GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary endpoint of progression-free survival.

The pharmaceutical giant said that the study compared its monotherapy Blenrep versus pomalidomide in combination with low dose dexamethasone and observed median progression-free survival was longer for Blenrep.

“These trials are designed to demonstrate the benefit of Blenrep in combination treatment with novel therapies and standard-of-care treatments in earlier lines of therapy and dosing optimization to maintain efficacy while reducing corneal events,” it added.

The company said additional trials will continue and further data from the studies are anticipated in the first half of 2023.

Write to Michael Susin at michael.susin@wsj.com

[ad_2]

Source link

November 7, 2022

Moderna Stock Takes Off on Cancer Vaccine News

[ad_1]

Moderna

stock shot up after

Merck

said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker.

Merck (ticker: MRK) will pay

Moderna

(MRNA) $250 million for the joint development and future commercialization of the vaccine, which is currently in Phase 2 clinical trials. The two companies had announced a “strategic collaboration” in June 2016.

[ad_2]

Source link

October 12, 2022

YourEncore® Joins AARP® Employer Pledge Program

[ad_1]

National effort helps employers solve staffing challenges, directs job seekers to employers that value and hire experience

Press Release
–

updated: Jun 12, 2017

Indianapolis, IN, June 12, 2017 (Newswire.com)
–
YourEncore, a leading provider of world-class expertise for flexible resourcing and consulting engagements to life sciences and consumer goods companies, has joined more than 450 organizations in signing the AARP Employer Pledge, confirming their commitment to hiring across the age spectrum and leveraging the value that experienced workers bring to companies of all sizes.

“YourEncore was founded on the core principle that experience matters,” said Mike Lewis, Chief Sales & Marketing Officer at YourEncore. “Our mission is to put experience to work. We offer clients the opportunity to tap into the most accomplished and experienced community of experts in the world, and we offer our talent community, or YourEncore Experts as we call them, the opportunity to use their experience to make a lasting difference. We are excited to join with AARP in its mission to drive awareness of the wisdom, experience, and technical skill of accomplished business professionals.”

“YourEncore was founded on the core principle that experience matters. We are excited to join with AARP in its mission to drive awareness of the wisdom, experience, and technical skill of accomplished business professionals. We’re passionate about creating the workforce of the future…one that is ageless, inspires and engages talent, and accelerates business performance. We look forward to working with AARP on this all-important journey.”

Mike Lewis, YourEncore Chief Sales & Marketing Officer

Employers are facing a chasm of wisdom, experience, and absolute talent supply that places achievement of their business objectives at risk. Over 10,000 Baby Boomers retire every day. While Millennials currently provide the workforce with a large infusion of talent, their numbers alone are still not enough to stem the tide of departing Boomers¹. This talent gap cannot be closed with traditional employment models. Given the seismic shifts taking place in today’s workforce, companies need to think differently about how they utilize talent, and individuals need to think differently about how they approach work. YourEncore is uniquely positioned to provide both groups with the solutions they need to successfully navigate and take advantage of this perfect storm that is today’s economy.

YourEncore combines cutting-edge technology and high-touch personal engagement to build robust, vibrant talent communities, match talent to business requirements, and create tailored talent solutions that allow clients to transform and grow and Experts to realize their personal and professional goals.

Although some Boomers are stepping away from traditional full-time, career-focused employment, many want to continue working, for a host of reasons from social to professional to financial². YourEncore is a leader in mobilizing this “encore workforce” and has helped thousands of Experts build successful consulting careers through rewarding project work and professional development.

For clients, YourEncore deploys world class expertise from their Expert Network to solve complex problems, support critical initiatives, and fill capability and capacity gaps. Experts are hand-picked and matched for subject matter expertise and business acumen. They are alumni from some of the best companies in the world, average over 25 years of experience, and the majority hold advanced degrees. The power of that experience – which the AARP Employer Pledge Program is designed to elevate – is the impetus behind the founding and on-going growth of YourEncore.

“We’re passionate about creating the workforce of the future…one that is ageless, inspires and engages talent, and accelerates business performance,” said Lewis. “We look forward to working with AARP on this all-important journey.”

About YourEncore®: YourEncore is a leading provider of proven expertise, delivering flexible resourcing and consulting services to the biopharma, medical devices and diagnostics, and consumer goods industries. YourEncore mobilizes the wisdom and knowledge of highly experienced, immediately effective Experts to help companies outthink, outpace, and outperform. Based in Indianapolis, IN, with offices in Cincinnati, OH and Princeton, NJ, YourEncore was named a “100 Most Brilliant Company” by Entrepreneur Magazine. For more information, visit yourencore.com and follow us on Facebook @YourEncore, Twitter @YourEncoreInc, and LinkedIn.

¹https://www.conference-board.org/laborshortages/

²https://www.transamericacenter.org/docs/default-source/retirement-survey-of-workers/tcrs2016_sr_perspectives_on_retirement_baby_boomers_genx_millennials.pdf

Media Contacts:

Mike Lewis 609.216.7903 mike.lewis@yourencore.com

Nancy Reilly 513.609.4516 nancy.reilly@yourencore.com

Source: YourEncore, Inc.

[ad_2]

Source link

June 12, 2017

Tag: Research/Development